WuXi AppTec launches new service to deliver more shots on goal for drug discovery

WuXi AppTec Expands Site in the United States
WuXi AppTec opens a New Jersey-based site. (PRNewsfoto/WuXi AppTec)

Shanghai-based WuXi AppTec has launched its so-called DELight service aimed at making “cost-effective and efficient hit finding services” to speed up early drug discovery.

DELight, or DNA Encoded Library, is a self-serve product that gives researchers direct access to a collection of more than 8 billion compounds.

“Through the DELight service package, WuXi will provide a DNA Encoded Library kit and a user manual/protocols document to the research organization,” the CRO and drug discovery company explained in a statement.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

RELATED: WuXi AppTec hires cancer drug development vet as new CMO

When a researcher gets hold of the kit, they make an affinity selection and then send it back to WuXi, which in turn will perform an analysis and send a summary report back to the researcher.

WuXi explains that when compared to traditional DNA-based drug discovery services, “DELight is a more convenient, efficient and economical service package, allowing researchers to perform their own affinity selection with minimum assay development and without disclosing target information.”

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.